- Home
- NXP vs MRVI Comparison
NXP vs MRVI Comparison
Compare NXP & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- MRVI
- Stock Information
- Founded
- NXP 1992
- MRVI 2020
- Country
- NXP United States
- MRVI United States
- Employees
- NXP N/A
- MRVI N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NXP Finance
- MRVI Health Care
- Exchange
- NXP Nasdaq
- MRVI Nasdaq
- Market Cap
- NXP 702.9M
- MRVI 809.2M
- IPO Year
- NXP N/A
- MRVI 2020
- Fundamental
- Price
- NXP $14.82
- MRVI $5.68
- Analyst Decision
- NXP
- MRVI Buy
- Analyst Count
- NXP 0
- MRVI 11
- Target Price
- NXP N/A
- MRVI $10.03
- AVG Volume (30 Days)
- NXP 70.0K
- MRVI 1.6M
- Earning Date
- NXP 01-01-0001
- MRVI 11-07-2024
- Dividend Yield
- NXP 4.04%
- MRVI N/A
- EPS Growth
- NXP N/A
- MRVI N/A
- EPS
- NXP 0.54
- MRVI N/A
- Revenue
- NXP N/A
- MRVI $276,920,000.00
- Revenue This Year
- NXP N/A
- MRVI N/A
- Revenue Next Year
- NXP N/A
- MRVI $3.41
- P/E Ratio
- NXP $26.81
- MRVI N/A
- Revenue Growth
- NXP N/A
- MRVI N/A
- 52 Week Low
- NXP $12.91
- MRVI $4.28
- 52 Week High
- NXP $14.89
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- NXP 47.43
- MRVI 49.01
- Support Level
- NXP $14.68
- MRVI $5.45
- Resistance Level
- NXP $15.08
- MRVI $6.01
- Average True Range (ATR)
- NXP 0.16
- MRVI 0.34
- MACD
- NXP -0.01
- MRVI 0.12
- Stochastic Oscillator
- NXP 19.85
- MRVI 63.43
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.